创模生物科技(北京)有限公司

CN / En

NEWS

Advantages of InnoModels' ADCC Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-10-17 15:53
  • Views:

(Summary description)InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment

Advantages of InnoModels' ADCC Platform

(Summary description)InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-10-17 15:53
  • Views:
Information

InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment:
Precise Targeting to Enhance Therapeutic Effectiveness
The core of the ADCC platform lies in the specific binding of antibodies to the antigens on the surface of tumor cells, which activates the killing effect of immune cells (e.g., NK cells) and achieves a precise strike on tumor cells. This type of targeted therapy has higher selectivity and lower side effects compared with traditional chemotherapy and radiotherapy, and can significantly enhance the treatment effect, bringing better quality of life and longer survival period to patients.
Diversified Experimental Services to Accelerate Drug Development
InnoModels' ADCC platform supports the combination of multiple types of tumor cells and immune cells for experiments, including tumor cell lines, primary tumor cells, genetically engineered cell lines, etc., as well as commercially-sourced and clinically-patient-sourced peripheral blood mononuclear cells (PBMC). This diversified experimental service system provides researchers with a rich choice of space, which can accelerate the development process of new drugs and shorten the translation time of drugs from the laboratory to the clinic.
Efficient Data Processing, Helping Research Decision Making
Equipped with an advanced data analysis system, the platform is capable of automated processing and analysis of experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can intuitively understand the experimental results through the visualization reports provided by the platform, thus better guiding subsequent research work and clinical decision-making. This efficient data processing capability saves researchers a great deal of time and effort, enabling them to focus more on research innovation and exploration.

 


Customized solutions to meet individual needs
InnoModels' ADCC platform is highly customizable and can be tailored to meet the specific needs of researchers. Whether it is cell type, drug treatment, experiment time or other experimental conditions, the platform can be flexibly adjusted to meet the diverse needs of different researchers. This flexibility gives the platform a unique advantage in personalized research on cancer treatment, and enables it to provide patients with more precise and effective treatment plans.
Promoting Industry-University-Research Cooperation and Technology Transformation
InnoModels Biotechnology has established close partnerships with leading biopharmaceutical companies and research institutions around the world to promote the innovation and application of ADCC technology. Through industry-university-research cooperation, the Company is able to fully utilize the advantages of all parties to accelerate the development and transformation of new technologies, bringing patients more cutting-edge and effective treatments. Meanwhile, the Company also actively participates in academic exchanges and cooperation at home and abroad to promote common progress and development in the field of tumor immunotherapy.
In summary, the ADCC platform of InnoModels Biotechnology has played an important role in promoting the progress of cancer treatment with its advantages of precise targeting, diversified experimental services, efficient data processing, customized solutions and industry-university-research cooperation. In the future, with the continuous development and improvement of the technology, the platform will continue to bring more hope and gospel to cancer patients.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司